Table 1 Basal characteristics of patients, overall and by extent of proteinuria reduction after six months of paricalcitol
Overall | Good Responders(ΔUprot≥30%) | Poor Responders(ΔUprot<30%) | P | |
|---|---|---|---|---|
N | 48 | 24 | 24 | |
Age (years) | 63 ± 14 | 64.1 ± 11.5 | 62.7 ± 16.9 | 0.735 |
Gender (M:F) | 42:6 | 22:2 | 20:4 | 0.666 |
Body Mass Index (Kg/m2) | 27.6 ± 4.4 | 27.9 ± 3.8 | 27.2 ± 5.1 | 0.593 |
Diabetes (% pts) | 19 (39.6) | 14 (58.3) | 5 (20.8) | 0.017 |
Previous CV events (% pts) | 18 (37.5) | 11 (45.8) | 7 (29.2) | 0.371 |
Renal Disease (pts) | DN (12), GN (10) HN (13), APKD (4) Pyelonephritis (2) Nephrectomy (1) Unknown (6) | DN (9), GN (6), HN (4), APKD (2) Pyelonephritis (1) Nephrectomy (0) Unknown (2) | DN (3), GN (4), HN (9), APKD (2) Pyelonephritis (1) Nephrectomy (1) Unknown (4) | 0.322 |
25-OH vitamin D (ng/mL) | 18.8 ± 10.0 | 19.9 ± 8.7 | 17.6 ± 11.2 | 0.433 |
eGFR (mL/min/1.73 m2) | 29.7 ± 14.5 | 35.5 ± 16.0 | 23.9 ± 10.1 | 0.004 |
Serum albumin (g/dL) | 4.1 ± 0.4 | 4.0 ± 0.5 | 4.2 ± 0.4 | 0.241 |
Proteinuria (g/day) | 1.23 (1.00-1.51) | 1.14 (0.81-1.61) | 1.32 (1.02-1.71) | 0.501 |
UNaV (mEq/day) | 161 ± 63 | 183 ± 60 | 141 ± 52 | 0.012 |
Systolic BP (mmHg) | 143 ± 22 | 146 ± 19 | 141 ± 24 | 0.453 |
Diastolic BP (mmHg) | 78 ± 11 | 78 ± 11 | 78 ± 12 | 0.980 |
Antihypertensive Drugs (n) | 3.6 ± 1.4 | 3.3 ± 1.4 | 3.8 ± 1.4 | 0.224 |
Anti-RAS per patient (n) | 1.6 ± 0.7 | 1.5 ± 0.7 | 1.6 ± 0.8 | 0.848 |
Furosemide (%) | 24 (50.0) | 14 (58.3) | 10 (41.7) | 0.387 |
Furosemide dose (mg/d) | 63 ± 30 | 60 ± 32 | 64 ± 31 | 0.742 |
CCB (%) | 25 (52.1) | 13 (54.2) | 12 (50.0) | 1.00 |
Beta Blocker (%) | 27 (56.3) | 17 (70.8) | 10 (41.7) | 0.080 |